아토피 피부염 치료제 개발을 위한 biomarkers와 약효 검색법

초록

Although atopic dermatitis (AD) is one of the most common skin disease, specially in children, it is poorly characterized of pathogenesis and is having difficulty for the development of therapeutic agent. Therefore we reviewed previous studies for atopic dermatitis biomarkers and screening method for the measurement of clinical severity, and suggest a development direction of atopic dermatitis therapeutic agent. Biomarkers for AD was investigated in terms of immune and genomic biomarkers, and main biomarkers of AD were focused on immune biomarkers based on the pathogenesis mechanism. The available immune biomarkers of AD were IgE, IL-4, IL-5, IL-6, IL10, IL-12 and IL18; the genomic biomarkers were chromosome 5q31-33, chromosome 16p12 and HLA-DRB1*15 gene. The screening method of AD has not been established, but SCORAD index was only applicable. SCORAD index measures three parameters, such as extent, intensity, subjective symptom, and is the most accurate and objective method to measure AD severity, and to identify the efficacy of therapeutic agent. Finally, this review article suggests good biomarkers and screening method for AD, and those would contribute to understand the pathogenesis of AD and to develop therapeutic agents.

키워드